{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:27:43Z","timestamp":1790404063240,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T00:00:00Z","timestamp":1551139200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00262-019-02311-1","type":"journal-article","created":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T02:12:23Z","timestamp":1551233543000},"page":"765-772","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis"],"prefix":"10.1007","volume":"68","author":[{"given":"Bastian","family":"Schilling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Martens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marnix H.","family":"Geukes Foppen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoffer","family":"Gebhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica C.","family":"Hassel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa A.","family":"Rozeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Gesierich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Gutzmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina C.","family":"K\u00e4hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Livingstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis T.","family":"Diamantopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Gogas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Madonna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo A.","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone M.","family":"Goldinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Mangana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Garbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Blank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Weide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,26]]},"reference":[{"issue":"6892","key":"2311_CR1","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H et al (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949\u2013954","journal-title":"Nature"},{"issue":"26","key":"2311_CR2","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364(26):2507\u20132516","journal-title":"N Engl J Med"},{"issue":"20","key":"2311_CR3","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","volume":"371","author":"GV Long","year":"2014","unstructured":"Long GV et al (2014) Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 371(20):1877\u20131888","journal-title":"N Engl J Med"},{"issue":"20","key":"2311_CR4","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","volume":"371","author":"J Larkin","year":"2014","unstructured":"Larkin J et al (2014) Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 371(20):1867\u20131876","journal-title":"N Engl J Med"},{"issue":"4","key":"2311_CR5","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372(4):320\u2013330","journal-title":"N Engl J Med"},{"issue":"26","key":"2311_CR6","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C et al (2015) Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 372(26):2521\u20132532","journal-title":"N Engl J Med"},{"issue":"1","key":"2311_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(1):23\u201334","journal-title":"N Engl J Med"},{"issue":"7","key":"2311_CR8","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1200\/JCO.2017.74.1025","volume":"36","author":"GV Long","year":"2018","unstructured":"Long GV et al (2018) Long-term outcomes in patients with BRAF V600\u2013mutant metastatic melanoma who received dabrafenib combined with trametinib. J Clin Oncol 36(7):667\u2013673","journal-title":"J Clin Oncol"},{"issue":"22","key":"2311_CR9","doi-asserted-by":"publisher","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-16-0127","volume":"22","author":"B Weide","year":"2016","unstructured":"Weide B et al (2016) Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab. Clin Cancer Res 22(22):5487\u20135496","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2311_CR10","doi-asserted-by":"publisher","first-page":"e0130142","DOI":"10.1371\/journal.pone.0130142","volume":"10","author":"L Carbognin","year":"2015","unstructured":"Carbognin L et al (2015) Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One 10(6):e0130142","journal-title":"PLoS One"},{"issue":"34","key":"2311_CR11","doi-asserted-by":"publisher","first-page":"4102","DOI":"10.1200\/JCO.2016.67.2477","volume":"34","author":"AI Daud","year":"2016","unstructured":"Daud AI et al (2016) Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J Clin Oncol 34(34):4102\u20134109","journal-title":"J Clin Oncol"},{"key":"2311_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ejca.2017.10.026","volume":"88","author":"K Schaper-Gerhardt","year":"2018","unstructured":"Schaper-Gerhardt K et al (2018) PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma. Eur J Cancer 88:67\u201376","journal-title":"Eur J Cancer"},{"issue":"4","key":"2311_CR13","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/pcmr.12670","volume":"31","author":"MJ Wongchenko","year":"2018","unstructured":"Wongchenko MJ et al (2018) Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib. Pigment Cell Melanoma Res 31(4):516\u2013522","journal-title":"Pigment Cell Melanoma Res"},{"issue":"9","key":"2311_CR14","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1093\/annonc\/mdv255","volume":"26","author":"D Massi","year":"2015","unstructured":"Massi D et al (2015) The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600. Ann Oncol 26(9):1980\u20131987","journal-title":"Ann Oncol"},{"issue":"36","key":"2311_CR15","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch CM et al (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27(36):6199\u20136206","journal-title":"J Clin Oncol"},{"issue":"4","key":"2311_CR16","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","volume":"17","author":"M Schemper","year":"1996","unstructured":"Schemper M, Smith TL (1996) A note on quantifying follow-up in studies of failure time. Control Clin Trials 17(4):343\u2013346","journal-title":"Control Clin Trials"},{"issue":"1","key":"2311_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/CJI.0000000000000148","volume":"40","author":"DB Johnson","year":"2017","unstructured":"Johnson DB et al (2017) Sequencing treatment in BRAFV600 mutant melanoma: anti-PD-1 before and after BRAF inhibition. J Immunother 40(1):31\u201335","journal-title":"J Immunother"},{"key":"2311_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ejca.2017.05.033","volume":"82","author":"D Schadendorf","year":"2017","unstructured":"Schadendorf D et al (2017) Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. Eur J Cancer 82:45\u201355","journal-title":"Eur J Cancer"},{"issue":"6","key":"2311_CR19","first-page":"417","volume":"14","author":"MB Atkins","year":"2016","unstructured":"Atkins MB (2016) What is optimal first-line treatment of unresectable or advanced BRAF-mutant melanoma? Clin Adv Hematol Oncol 14(6):417\u2013419","journal-title":"Clin Adv Hematol Oncol"},{"issue":"Suppl 5","key":"2311_CR20","doi-asserted-by":"publisher","first-page":"v126","DOI":"10.1093\/annonc\/mdv297","volume":"26","author":"R Dummer","year":"2015","unstructured":"Dummer R et al (2015) Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26(Suppl 5):v126\u2013v132","journal-title":"Ann Oncol"},{"issue":"6","key":"2311_CR21","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/CCO.0000000000000405","volume":"29","author":"IP Silva","year":"2017","unstructured":"Silva IP, Long GV (2017) Systemic therapy in advanced melanoma: integrating targeted therapy and immunotherapy into clinical practice. Curr Opin Oncol 29(6):484\u2013492","journal-title":"Curr Opin Oncol"},{"issue":"4","key":"2311_CR22","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/CMR.0000000000000455","volume":"28","author":"PA Ascierto","year":"2018","unstructured":"Ascierto PA et al (2018) The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study. Melanoma Res 28(4):333\u2013340","journal-title":"Melanoma Res"},{"issue":"15_suppl","key":"2311_CR23","doi-asserted-by":"publisher","first-page":"9021","DOI":"10.1200\/jco.2015.33.15_suppl.9021","volume":"33","author":"B Dr\u00e9no","year":"2015","unstructured":"Dr\u00e9no B et al (2015) Quality-of-life (QOL) assessment in patients (pts) with metastatic melanoma receiving vemurafenib (V) and cobimetinib (C). J Clin Oncol 33(15_suppl):9021\u20139021","journal-title":"J Clin Oncol"},{"issue":"1","key":"2311_CR24","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1158\/2159-8290.CD-13-0617","volume":"4","author":"EM Allen Van","year":"2014","unstructured":"Van Allen EM et al (2014) The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 4(1):94\u2013109","journal-title":"Cancer Discov"},{"issue":"15_suppl","key":"2311_CR25","doi-asserted-by":"publisher","first-page":"9520","DOI":"10.1200\/JCO.2017.35.15_suppl.9520","volume":"35","author":"PA Ascierto","year":"2017","unstructured":"Ascierto PA et al (2017) Initial efficacy of anti-lymphocyte activation gene-3 (anti-LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti-PD-1\/PD-L1 therapy. J Clin Oncol 35(15_suppl):9520\u20139520","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"2311_CR26","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1200\/JCO.2018.36.15_suppl.108","volume":"36","author":"GV Long","year":"2018","unstructured":"Long GV et al (2018) Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: results of the phase 3 ECHO-301\/KEYNOTE-252 study. J Clin Oncol 36(15_suppl):108\u2013108","journal-title":"J Clin Oncol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-019-02311-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-019-02311-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-019-02311-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,12]],"date-time":"2022-09-12T17:49:38Z","timestamp":1663004978000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-019-02311-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,26]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["2311"],"URL":"https:\/\/doi.org\/10.1007\/s00262-019-02311-1","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,26]]},"assertion":[{"value":"9 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Bastian Schilling reports advisory roles for or has received honoraria from Pierre Fabre Pharmaceuticals, Incyte, Novartis, Roche, Bristol-Myers Squibb (BMS) and Merck Sharp & Dohme (MSD), research funding from BMS, Pierre Fabre Pharmaceuticals and MSD, and travel support from Novartis, Roche, BMS, Pierre Fabre Pharmaceuticals and Amgen. Christoffer Gebhardt reports advisory roles for or has received honoraria from Pierre Fabre Pharmaceuticals, Beiersdorf, BMS, MSD, Novartis, Roche and Sysmex, and travel support from BMS, MSD, Novartis and Roche. Jessica C. Hassel reports advisory roles for Pierre Fabre and Sanofi, and honoraria from BMS, MSD, Novartis, Roche and Pfizer. Anja Gesierich reports advisory roles for BMS, MSD, Novartis, Roche and Pfizer, has received honoraria from MSD and BMS, and travel support from BMS, MSD, Novartis and Roche. Ralf Gutzmer reports advisory roles for Roche, BMS, MSD, Amgen, Almirall, Leo, Pfizer, Novartis, GlaxoSmithKline (GSK), Incyte, Merck and Pierre-Fabre, has received honoraria from Roche, BMS, MSD, GSK, Novartis, Merck, Almirall, Amgen, Galderma, Astra-Zeneca and Pierre-Fabre, research funding from Novartis, Johnson & Johnson and Pfizer, honoraria from Roche, BMS, MSD, GSK, Novartis, Merck, Almirall, Amgen, Galderma, Astra-Zeneca and Pierre-Fabre, and travel support from Roche, BMS, MSD, GSK, Novartis, Merck, Almirall, Amgen, Galderma, Astra-Zeneca and Pierre-Fabre. Elisabeth Livingstone reports advisory roles for Roche, BMS, Novartis and Actelion, has received honoraria from Roche, BMS, MSD, Amgen, Novartis, Boehringer-Ingelheim (BI) and medac, and travel support from Roche, BMS, MSD, Amgen, Novartis, BI and medac. Panagiotis T. Diamantopoulos reports honoraria from Novartis and Roche, and travel support from Roche, Novartis, Janssen and Amgen. Helen Gogas reports honoraria from BMS, Roche, MSD, Novartis, Amgen and Pierre Fabre, and research funding from BMS, Roche, MSD and Novartis. Simone M. Goldinger reports advisory roles for Roche, Novartis, MSD and BMS, and has received travel support from Roche, Novartis, MSD and BMS. Joanna Mangana reports advisory roles for Merck and Pfizer, has received research funding from BMS, and travel support from MSD. Claus Garbe reports advisory roles for Amgen, BMS, MSD, Philogen, Roche and LEO Pharma, has received honoraria from Novartis, Amgen, BMS, MSD, Philogen, Roche and LEO Pharma, and research funding from Novartis, BMS and Roche. Dirk Schadendorf has received honoraria from Roche Pharma, BMS, Novartis, Merck Serono, MSD, Amgen, Incyte, LEO, Pfizer, Pierre Fabre, Array, Astra Zeneca, Regeneron, Philogen, Sanofi and Mologen, and research funding from Novartis and BMS. Christian Blank reports advisory roles for BMS, MSD, Roche, Novartis, GSK, Lilly, Pfizer and Genmab, and has received research funding from Novartis and BMS. Benjamin Weide has received honoraria from Merck\/MSD, BMS, Philogen, Curevac, Roche, Novartis and Amgen, research funding from MSD and BMS, and travel support from MSD and BMS. All other authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Retrospective collection of anonymous patient data was performed during routine clinical care. This study was approved by the Ethics Committee, University of T\u00fcbingen (approvals 524\/2012BO2 and 234\/2015BO2).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For anonymous publication of retrospective data acquired during routine clinical care, individual informed consents were not obtained.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}